Synopsis
Synopsis
0
CEP/COS
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
2. Galvus
3. Nvp Laf237
4. Nvp-laf237
5. Vildagliptin
1. Vildagliptin
2. 274901-16-5
3. (2r)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
4. Vildagliptin (2r)-isomer
5. Schembl671629
6. Dtxsid301119534
7. Akos015969326
8. F78360
9. A819091
10. (2r)-1-[2-[(3-hydroxy-1-adamantyl)amino]-1-oxoethyl]-2-pyrrolidinecarbonitrile
11. (2r)-1-[2-[(3-oxidanyl-1-adamantyl)amino]ethanoyl]pyrrolidine-2-carbonitrile
12. (2r)-1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidine Carbonitrile; (r)-1-(2-(((1r,3s,5r,7s)-3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
13. Rel-(2r)-1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile
1. Jalra
2. Equa
| Molecular Weight | 303.4 g/mol |
|---|---|
| Molecular Formula | C17H25N3O2 |
| XLogP3 | 0.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 303.19467705 g/mol |
| Monoisotopic Mass | 303.19467705 g/mol |
| Topological Polar Surface Area | 76.4 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 523 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
- as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 and 5. 1 for available data on different combinations).
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
- as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 and 5. 1 for available data on different combinations).
Treatment of type II diabetes mellitus
Dipeptidyl-Peptidase IV Inhibitors
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. (See all compounds classified as Dipeptidyl-Peptidase IV Inhibitors.)
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
A10BH02
A10BH02
A10BH02
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
A10BH02 - Vildagliptin
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
97
PharmaCompass offers a list of Vildagliptin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vildagliptin manufacturer or Vildagliptin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vildagliptin manufacturer or Vildagliptin supplier.
PharmaCompass also assists you with knowing the Vildagliptin API Price utilized in the formulation of products. Vildagliptin API Price is not always fixed or binding as the Vildagliptin Price is obtained through a variety of data sources. The Vildagliptin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 274901-16-5 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 274901-16-5, including repackagers and relabelers. The FDA regulates 274901-16-5 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 274901-16-5 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 274901-16-5 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 274901-16-5 supplier is an individual or a company that provides 274901-16-5 active pharmaceutical ingredient (API) or 274901-16-5 finished formulations upon request. The 274901-16-5 suppliers may include 274901-16-5 API manufacturers, exporters, distributors and traders.
click here to find a list of 274901-16-5 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 274901-16-5 DMF (Drug Master File) is a document detailing the whole manufacturing process of 274901-16-5 active pharmaceutical ingredient (API) in detail. Different forms of 274901-16-5 DMFs exist exist since differing nations have different regulations, such as 274901-16-5 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 274901-16-5 DMF submitted to regulatory agencies in the US is known as a USDMF. 274901-16-5 USDMF includes data on 274901-16-5's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 274901-16-5 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 274901-16-5 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 274901-16-5 Drug Master File in Japan (274901-16-5 JDMF) empowers 274901-16-5 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 274901-16-5 JDMF during the approval evaluation for pharmaceutical products. At the time of 274901-16-5 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 274901-16-5 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 274901-16-5 Drug Master File in Korea (274901-16-5 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 274901-16-5. The MFDS reviews the 274901-16-5 KDMF as part of the drug registration process and uses the information provided in the 274901-16-5 KDMF to evaluate the safety and efficacy of the drug.
After submitting a 274901-16-5 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 274901-16-5 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 274901-16-5 suppliers with KDMF on PharmaCompass.
A 274901-16-5 written confirmation (274901-16-5 WC) is an official document issued by a regulatory agency to a 274901-16-5 manufacturer, verifying that the manufacturing facility of a 274901-16-5 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 274901-16-5 APIs or 274901-16-5 finished pharmaceutical products to another nation, regulatory agencies frequently require a 274901-16-5 WC (written confirmation) as part of the regulatory process.
click here to find a list of 274901-16-5 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 274901-16-5 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 274901-16-5 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 274901-16-5 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 274901-16-5 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 274901-16-5 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 274901-16-5 suppliers with NDC on PharmaCompass.
274901-16-5 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 274901-16-5 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 274901-16-5 GMP manufacturer or 274901-16-5 GMP API supplier for your needs.
A 274901-16-5 CoA (Certificate of Analysis) is a formal document that attests to 274901-16-5's compliance with 274901-16-5 specifications and serves as a tool for batch-level quality control.
274901-16-5 CoA mostly includes findings from lab analyses of a specific batch. For each 274901-16-5 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
274901-16-5 may be tested according to a variety of international standards, such as European Pharmacopoeia (274901-16-5 EP), 274901-16-5 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (274901-16-5 USP).
